Tokyo, Sept. 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059234) titled 'Single-center prospective observational study investigating the impact of beta1 adrenergic receptor and its auto-antibody on responsiveness of beta-blocker in heart failure therapy' on Sept. 29.
Study Type:
Observational
Primary Sponsor:
Institute - Hamamatsu University School of Medicine
Condition:
Condition - heart failure
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - To investigate the relationship between clinical efficacy and genetic polymorphisms of beta1 adrenergic receptor and its auto-antibody in heart failure with beta-blocker.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who are 18 years of age or older at the time of consent.
Patients diagnosed heart failure newly introduced to beta-blocker as treatment for heart failure.
Patients who have been fully informed of the study and who have given written consent of their own free will.
Key exclusion criteria - Patients with significantly poor medication adherence
Patients with advanced cancer
Patients with a history of autoimmune disease.
Patients deemed inappropriate by the attending physician, etc.
Target Size - 100
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2024 Year 04 Month 02 Day
Date of IRB - 2023 Year 12 Month 04 Day
Anticipated trial start date - 2024 Year 08 Month 01 Day
Last follow-up date - 2030 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067752
Disclaimer: Curated by HT Syndication.
